Glioblastoma in adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions Review


Authors: Wen, P. Y.; Weller, M.; Lee, E. Q.; Alexander, B. M.; Barnholtz-Sloan, J. S.; Barthel, F. P.; Batchelor, T. T.; Bindra, R. S.; Chang, S. M.; Chiocca, E. A.; Cloughesy, T. F.; DeGroot, J. F.; Galanis, E.; Gilbert, M. R.; Hegi, M. E.; Horbinski, C.; Huang, R. Y.; Lassman, A. B.; Le Rhun, E.; Lim, M.; Mehta, M. P.; Mellinghoff, I. K.; Minniti, G.; Nathanson, D.; Platten, M.; Preusser, M.; Roth, P.; Sanson, M.; Schiff, D.; Short, S. C.; Taphoorn, M. J. B.; Tonn, J. C.; Tsang, J.; Verhaak, R. G. W.; von Deimling, A.; Wick, W.; Zadeh, G.; Reardon, D. A.; Aldape, K. D.; van den Bent, M. J.
Review Title: Glioblastoma in adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
Abstract: Glioblastomas are the most common form of malignant primary brain tumor and an important cause of morbidity and mortality. In recent years there have been important advances in understanding the molecular pathogenesis and biology of these tumors, but this has not translated into significantly improved outcomes for patients. In this consensus review from the Society for Neuro-Oncology (SNO) and the European Association of Neuro-Oncology (EANO), the current management of isocitrate dehydrogenase wildtype (IDHwt) glioblastomas will be discussed. In addition, novel therapies such as targeted molecular therapies, agents targeting DNA damage response and metabolism, immunotherapies, and viral therapies will be reviewed, as well as the current challenges and future directions for research.
Keywords: glioblastoma; diagnosis; therapy; clinical trials; metastatic; placebo-controlled trial; phase-iii; randomized; molecular-weight heparin; central-nervous-system; brain-tumors; progression-free survival; apparent diffusion-coefficient; newly-diagnosed glioblastoma; gliomas response assessment; depatuxizumab mafodotin abt-414
Journal Title: Neuro-Oncology
Volume: 22
Issue: 8
ISSN: 1522-8517
Publisher: Oxford University Press  
Date Published: 2020-08-01
Start Page: 1073
End Page: 1113
Language: English
ACCESSION: WOS:000593120100008
DOI: 10.1093/neuonc/noaa106
PROVIDER: wos
PMCID: PMC7594557
PUBMED: 32328653
Notes: Review -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors